Brian Druker
Brian J. Druker, M.D. (born April 30, 1955) is an American physician-scientist and JELD-WEN Chair of Leukemia Research at Oregon Health & Science University (OHSU) in Portland, Oregon. In 2025, he was named the inaugural president of the newly independent Knight Cancer Group, a self-governing entity formed by the Oregon Health & Science University's Knight Cancer Institute following a record $2 billion gift from Phil and Penny Knight. He previously served as chief executive officer and director of OHSU's Knight Cancer Institute, as well as Associate Dean for Oncology in the OHSU School of Medicine.Druker helped develop imatinib (Gleevec), the first medication that specifically targets cancer cells, for the treatment of chronic myeloid leukemia (CML). In 2001, Gleevec gained FDA approval in record time and landed on the cover of ''Time'' magazine. Druker’s work launched the era of precision cancer medicine, setting the stage for future discoveries in the quest to end cancer.
He is the recipient of the 2009 Lasker-DeBakey Clinical Medical Research Award, the 2012 Japan Prize in Healthcare and Medical Technology, the 2013 Albany Medical Center Prize in Medicine and Biomedical Research, and the 2019 Sjöberg Prize, among others. He has been called "Oregon's best-known scientist". Provided by Wikipedia
-
1